DyAnsys has received US Food and Drug Administration (FDA) approval for its percutaneous electrical neurostimulation (PENS) device, called First Relief, to treat diabetic neuropathic pain.
First Relief is intended for symptomatic relief of chronic, intractable pain related to diabetic peripheral neuropathy through multiple treatments for up to 56 days.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Placed behind the ear, the wearable device provides continuous pulses of low-level electrical current for several days.
DyAnsys CEO Srini Nageshwar said: “We are excited to have the FDA clearance of First Relief so that this device, which has been proven effective, can now be used to treat patients who have been experiencing pain related to diabetic neuropathy.
“First Relief offers a significant treatment option without drugs or narcotics.”
The regulatory approval was based on data obtained from a randomised, double-blind, single-centre, controlled prospective study, which was conducted with 63 participants aged between 30 and 74 years.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn the study, First Relief was evaluated against a placebo, as well as another device that had previously been approved by the US FDA.
The devices were applied for a period of 16 weeks on a bi-weekly basis.
Pain intensity was measured through the Visual Analog Scale (VAS) score as the study’s primary efficacy endpoint.
The insomnia severity index (ISI), vibration perception threshold (VPT) value, total neuropathy limitations scale (ONLS) and Hamilton rating scale for anxiety were measured as some of the study’s secondary endpoints.
Based on the findings from the study, subjects treated with First Relief experienced a significant reduction in VAS pain score from the start of treatment to the end, with the improvements continuing throughout 90 days of follow-up.
This suggests that the device can provide long-term improvement in neuropathic pain.
DyAnsys noted that similar improvements were also observed for all secondary endpoints, demonstrating significant improvement in sleep and mood alongside a decrease in neuropathic pain.
